(UroToday.com) The second Urothelial Cancer session at this year’s European Association of Urology (EAU) Section of Oncological Urology (ESOU) virtual annual meeting featured a number of presentations, focussing on controversies in the management of urothelial cancers. The first presentation in this session was from Dr. Andrea Necchi who discussed the indications and controversies surrounding the use of neoadjuvant compared to adjuvant chemotherapy/immunotherapy in patients with high-risk upper tract urothelial carcinoma (UTUC).